Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma

Conclusions GD2 expression was found to persist upon recurrence. These results suggest a phase 2 trial in children with recurrent osteosarcoma should provide an appropriate read out on the efficacy of anti-GD2 antibody.

http://link.springer.com/10.1186/s13569-014-0020-9

Source: Clinical Sarcoma Research - January 24, 2015 Category: Cancer & Oncology Source Type: research